BAYRY
Bayer AG (ADR)

2,774
Mkt Cap
$42.56B
Volume
611,912.00
52W High
$14.85
52W Low
$6.20
PE Ratio
-9.77
BAYRY Fundamentals
Price
$10.83
Prev Close
$11.11
Open
$11.01
50D MA
$11.42
Beta
0.46
Avg. Volume
1.48M
EPS (Annual)
-$1.04
P/B
1.40
Rev/Employee
$583,970.35
$77,587.35
Loading...
Loading...
News
all
press releases
Regeneron Q1 Earnings Top, Sales Up on Dupixent & Eylea HD Strength
REGN tops Q1 estimates with strong Dupixent and Eylea HD growth, but the stock slips as Eylea sales plunge and competition intensifies.
Zacks·6d ago
News Placeholder
More News
News Placeholder
Regeneron Wins FDA Nod for Extended Eylea HD Dosing Interval
REGN wins FDA nod to extend Eylea HD dosing to 20 weeks, boosting flexibility for wAMD and DME patients while reinforcing its push to offset declining Eylea sales.
Zacks·29d ago
News Placeholder
Bayer Advances AB-1002 Study, Highlights Pharma Growth Strategy
Bayer advances AB-1002 after AskBio completes mid-stage study enrollment, as its Pharma strategy and pipeline milestones drive long-term growth outlook.
Zacks·1mo ago
News Placeholder
Bayer Wins EC Approval to Expand Kerendia in Heart Failure Treatment
Bayer wins EU nod to expand Kerendia's use in heart failure, backed by strong phase III data, boosting a key drug driving growth and portfolio momentum.
Zacks·1mo ago
News Placeholder
REGN Soars 28.9% in Six Months: Is There More Upside Potential in 2026?
Regeneron's rally reflects biotech momentum as pipeline wins and Dupixent growth offset Eylea erosion amid intensifying competition.
Zacks·1mo ago
News Placeholder
BAYRY Reports Positive Data on Kidney Drug in Non-Diabetic CKD
Bayer's finerenone hits key phase III goal in non-diabetic CKD, paving the way to expand Kerendia???s use as data strengthens its cardiorenal therapy role.
Zacks·2mo ago
News Placeholder
Bayer Advances Roundup Settlement With Missouri Court Approval
BAYRY wins preliminary court approval for a proposed Roundup class settlement, a key step in managing long-running glyphosate litigation and future liabilities.
Zacks·2mo ago
News Placeholder
Bayer Q4 Earnings Match Estimates, Xarelto and Eylea Pull Down Sales
BAYRY posts in-line Q4 earnings but revenues miss on lower Xarelto and Eylea sales. 2026 sales guidance signals steady growth ahead.
Zacks·2mo ago
News Placeholder
Here's Why Bayer Aktiengesellschaft (BAYRY) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks·2mo ago
News Placeholder
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Sanofi and Bayer
LLY, JNJ, SNY and BAYRY ride strong pipelines and M&A momentum as Large-Cap Pharma rebounds in 2026 despite pricing and patent risks.
Zacks·2mo ago
<
1
2
...
>

Latest BAYRY News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.